Jeffeires

Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) fell more than 40 percent and touched a new 52-week low. Jefferies downgraded the stock to Hold from Buy following not-so-impressive clinical data. "We believe accumulating data from MRTX and others at ASCO disclosed this weekend continues...